NO20050455L - Parenterale formuleringer inneholdende en rapamycinhydroksyester - Google Patents

Parenterale formuleringer inneholdende en rapamycinhydroksyester

Info

Publication number
NO20050455L
NO20050455L NO20050455A NO20050455A NO20050455L NO 20050455 L NO20050455 L NO 20050455L NO 20050455 A NO20050455 A NO 20050455A NO 20050455 A NO20050455 A NO 20050455A NO 20050455 L NO20050455 L NO 20050455L
Authority
NO
Norway
Prior art keywords
formulations containing
parenteral formulations
hydroxy ester
rapamycin
rapamycin hydroxy
Prior art date
Application number
NO20050455A
Other languages
English (en)
Inventor
Joseph Thomas Rubino
Victoria Siskavich
Maureen M Harrison
Pooja Gandhi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188593&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050455(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20050455L publication Critical patent/NO20050455L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer parenterale preparater av rapamycin 42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre (CCI-779).
NO20050455A 2002-07-30 2005-01-26 Parenterale formuleringer inneholdende en rapamycinhydroksyester NO20050455L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39952602P 2002-07-30 2002-07-30
PCT/US2003/023276 WO2004011000A1 (en) 2002-07-30 2003-07-25 Parenteral formulations containing a rapamycin hydroxyester

Publications (1)

Publication Number Publication Date
NO20050455L true NO20050455L (no) 2005-02-09

Family

ID=31188593

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050455A NO20050455L (no) 2002-07-30 2005-01-26 Parenterale formuleringer inneholdende en rapamycinhydroksyester

Country Status (28)

Country Link
US (4) US8026276B2 (no)
EP (1) EP1553940B1 (no)
JP (2) JP2005537285A (no)
KR (1) KR101131794B1 (no)
CN (1) CN100402031C (no)
AR (2) AR040693A1 (no)
AT (1) ATE385795T1 (no)
AU (2) AU2003254168A1 (no)
BR (1) BR0313024A (no)
CA (1) CA2493878C (no)
CO (1) CO5700745A2 (no)
CR (1) CR7647A (no)
DE (1) DE60319118T2 (no)
DK (1) DK1553940T3 (no)
EC (1) ECSP055628A (no)
ES (1) ES2300622T3 (no)
HK (1) HK1076390A1 (no)
IL (1) IL166003A (no)
MX (1) MXPA05001013A (no)
NO (1) NO20050455L (no)
NZ (1) NZ537829A (no)
PT (1) PT1553940E (no)
RU (1) RU2344821C2 (no)
SI (1) SI1553940T1 (no)
TW (1) TWI307277B (no)
UA (1) UA82328C2 (no)
WO (1) WO2004011000A1 (no)
ZA (1) ZA200500831B (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
AU2003272489B2 (en) * 2002-09-17 2008-11-13 Wyeth Granulated formulation of the rapamycin ester CCI779
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
EP1648454A1 (en) * 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
WO2005100366A1 (en) 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
MXPA06011881A (es) 2004-04-14 2006-12-14 Wyeth Corp Sintesis regioespecifica de derivados de ester-42 de rapamicina.
US20050239178A1 (en) * 2004-04-27 2005-10-27 Wyeth Labeling of rapamycin using rapamycin-specific methylases
CN101048152A (zh) * 2004-10-28 2007-10-03 惠氏公司 mTOR抑制剂在治疗子宫平滑肌瘤中的应用
WO2006086744A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
PE20070763A1 (es) 2005-11-04 2007-08-08 Wyeth Corp COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272
WO2007056175A2 (en) * 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
WO2007075621A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities
AU2013200089B2 (en) * 2006-02-09 2016-03-03 Santen Pharmaceutical Co., Ltd Stable formulations, and methods of their preparation and use
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
EP2271214B1 (en) * 2008-03-28 2017-05-03 Particle Sciences, Inc. Pharmaceutical solutions and method for solubilizing therapeutic agents
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
WO2011094565A1 (en) * 2010-01-28 2011-08-04 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
WO2011151704A2 (en) 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
US20120252835A1 (en) * 2011-04-01 2012-10-04 Astron Research Limited Stable temsirolimus composition and process of preparing same
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
PL2827862T3 (pl) 2012-03-20 2024-05-06 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
LT2827863T (lt) 2012-03-20 2019-06-10 Eagle Pharmaceuticals, Inc. Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
CN103989676B (zh) * 2014-06-10 2016-06-22 福建省微生物研究所 可注射用的替西罗莫司组合物
WO2017047618A1 (ja) * 2015-09-18 2017-03-23 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
US10765665B2 (en) 2015-11-24 2020-09-08 Melin Jeffrey Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases
CN105640878A (zh) * 2016-01-25 2016-06-08 宿州学院 一种坦西莫司注射用浓溶液及其制备方法
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107550852B (zh) * 2016-06-30 2021-05-14 山东新时代药业有限公司 一种坦西莫司注射液注射用溶剂及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN109996549A (zh) * 2016-09-22 2019-07-09 墨卡托医疗***公司 使用坦罗莫司治疗再狭窄
WO2018218182A1 (en) 2017-05-26 2018-11-29 Mercator Medsystems, Inc. Combination therapy for treatment of restenosis
EP3755303A1 (en) * 2018-02-23 2020-12-30 Biotronik AG Parenteral formulation materials and methods for 40-o-cyclic hydrocarbon esters and related structures
CN110382019B (zh) 2018-03-14 2020-08-25 墨卡托医疗***公司 用于局部药物递送的医疗器械和医疗方法
CN114366715A (zh) * 2022-01-28 2022-04-19 严鹏科 雷帕霉素自微乳注射剂及其制备方法及其应用

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) * 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US4316885A (en) * 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4650803A (en) * 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
GB8803836D0 (en) 1988-02-18 1988-03-16 Glaxo Group Ltd Compositions
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) * 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5162333A (en) * 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
NZ251628A (en) 1992-03-30 1996-07-26 American Home Prod Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) * 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
IL111008A (en) * 1993-09-30 1999-10-28 American Home Prod Rapamycin formulations for intravenous injection and their preparation
US5516770A (en) * 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation
US5616588A (en) * 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US6022852A (en) * 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
GB2327611B (en) * 1994-10-26 1999-06-02 Novartis Ag Macrolide compositions
IL129547A (en) * 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
WO1999056727A2 (en) 1998-05-07 1999-11-11 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US6455543B1 (en) * 1999-07-30 2002-09-24 University Of Kentucky Research Foundation Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
WO2001034816A1 (en) * 1999-10-29 2001-05-17 Kosan Biosciences, Inc. Rapamycin analogs
US20020013335A1 (en) 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
CA2421485A1 (en) * 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
US6399626B1 (en) * 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
NZ542048A (en) 2001-07-18 2008-04-30 Bionomics Ltd Mutations in ion channels
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
ES2246409T3 (es) * 2001-08-22 2006-02-16 Wyeth 29-enoles de rapamicina.
US20030176455A1 (en) 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
CA2501863A1 (en) * 2002-10-11 2004-04-22 Erasmus Universiteit Rotterdam Nucleic acid amplification primers for pcr-based clonality studies
BRPI0412659A (pt) 2003-07-16 2006-09-26 Wyeth Corp isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
EP1648454A1 (en) * 2003-07-25 2006-04-26 Wyeth Cci-779 lyophilized formulations
WO2005016935A2 (en) * 2003-08-07 2005-02-24 Wyeth Regioselective synthesis of cci-779
MXPA06011881A (es) 2004-04-14 2006-12-14 Wyeth Corp Sintesis regioespecifica de derivados de ester-42 de rapamicina.
PL1735321T3 (pl) * 2004-04-14 2009-04-30 Wyeth Corp Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
WO2005100366A1 (en) * 2004-04-14 2005-10-27 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
PE20060642A1 (es) * 2004-08-10 2006-08-01 Wyeth Corp Derivados de 42-ester de rapamicina con acido 2,2-bis(hidoximetil)propionico (cci-779) y metodos para su preparacion
AR050374A1 (es) * 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
MX2007007408A (es) * 2004-12-20 2007-07-12 Wyeth Corp Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios.
BRPI0519593A2 (pt) * 2004-12-20 2009-02-25 Wyeth Corp composto, mÉtodos de tratar distérbios neurodegenerativos e complicaÇÕes devido a derrame ou trauma na cabeÇa, e de preparar um composto, e, uso de um composto
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
AU2006218918A1 (en) * 2005-03-02 2006-09-08 Wyeth Purification of rapamycin
KR20080077619A (ko) * 2005-12-07 2008-08-25 와이어쓰 라파마이신 42-에스테르 보로네이트로부터 라파마이신42-에스테르를 제조하는 가변적인 방법
WO2007075621A1 (en) 2005-12-20 2007-07-05 Wyeth Control of cci-779 dosage form stability through control of drug substance impurities

Also Published As

Publication number Publication date
ZA200500831B (en) 2007-07-25
AU2010200761A1 (en) 2010-03-18
MXPA05001013A (es) 2005-05-16
US20040167152A1 (en) 2004-08-26
AU2010200761B2 (en) 2011-10-13
IL166003A (en) 2009-05-04
DK1553940T3 (da) 2008-06-02
US8026276B2 (en) 2011-09-27
CA2493878A1 (en) 2004-02-05
PT1553940E (pt) 2008-05-09
HK1076390A1 (en) 2006-01-20
IL166003A0 (en) 2006-01-15
EP1553940A1 (en) 2005-07-20
US8455539B2 (en) 2013-06-04
RU2005105301A (ru) 2005-09-10
NZ537829A (en) 2006-09-29
SI1553940T1 (sl) 2008-08-31
CR7647A (es) 2006-05-26
CN1671385A (zh) 2005-09-21
UA82328C2 (uk) 2008-04-10
JP2005537285A (ja) 2005-12-08
US8722700B2 (en) 2014-05-13
WO2004011000A1 (en) 2004-02-05
CN100402031C (zh) 2008-07-16
ECSP055628A (es) 2005-05-30
CA2493878C (en) 2013-07-23
DE60319118D1 (de) 2008-03-27
KR20050026025A (ko) 2005-03-14
EP1553940B1 (en) 2008-02-13
US20130252998A1 (en) 2013-09-26
US8299116B2 (en) 2012-10-30
KR101131794B1 (ko) 2012-03-30
BR0313024A (pt) 2005-07-12
CO5700745A2 (es) 2006-11-30
JP2010163466A (ja) 2010-07-29
AR090603A2 (es) 2014-11-26
TWI307277B (en) 2009-03-11
AR040693A1 (es) 2005-04-13
US20130040980A1 (en) 2013-02-14
TW200403073A (en) 2004-03-01
JP5345105B2 (ja) 2013-11-20
ES2300622T3 (es) 2008-06-16
ATE385795T1 (de) 2008-03-15
RU2344821C2 (ru) 2009-01-27
AU2003254168A1 (en) 2004-02-16
US20110294845A1 (en) 2011-12-01
DE60319118T2 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
HK1084050A1 (en) Granulate formulation of the rapamycin ester cci-779
SG145716A1 (en) Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
HUP0400521A2 (hu) A CCI-779 alkalmazása daganatellenes szerként
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
CA2368993A1 (en) C7 ester substituted taxanes as antitumor agents
AU7666194A (en) Novel peptide derivative
BR9804214A (pt) Compostos.
ATE170867T1 (de) Immunsuppressive aminomethylen-peptide
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
ATE386742T1 (de) Imidazonaphthyridine
CL2007002988A1 (es) Proceso para la preparacion de un isomero individual de rapamicina 42 ester con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico (cci-779) monopegilado.
IS5161A (is) Tetrahýdrópýridóefnasambönd
ATE172985T1 (de) Sulfonamidaminomethylenderivate als immunsuppressiva
NO20062271L (no) CCI-779 for behandling av mantle celle lymfom
DE60138853D1 (de) C10-taxanester als antitumormittel
DE60010276T2 (de) Neuartige vitamin-d analoge
WO2000069843A3 (en) Cycloalkyl substituted 3-urea-benzofurane-and -pyridofurane-derivatives
TR199901284A2 (xx) Ester bile�imleri.
AU2003271057A1 (en) Novel crystals of triazaspiro(5.5)undecane derivative
MXPA01007972A (es) Esteres de taxanos c10 sustituidos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application